7-bromo-6-chloro-3-[3-[(3R)-3-hydroxypiperidin-2-yl]-2-oxopropyl]quinazolin-4-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 7-bromo-6-chloro-3-[3-[(3R)-3-hydroxypiperidin-2-yl]-2-oxopropyl]quinazolin-4-one
• 化学式: C₁₆H₁₇BrClN₃O₃
• 分子量: 414.7
• InChiKey: LVASCWIMLIKXLA-YSSOQSIOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  82
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• Inhibition of pathogenic processes related to tissue trauma
  申请人：Pines Mark

  公开号：US20070010538A1

  公开（公告）日：2007-01-11

  According to the present invention compositions and methods are provided to prevent the pathogenic aspects of tissue trauma while preserving normal tissue repair mechanisms, based on the fact that these molecules abrogate the cascade of damage initiated by tissue trauma, while maintaining this the requisite healthy extracellular matrix economy. The composition for regulating the extracellular matrix economy, comprise a pharmaceutically effective amount of an effector in combination with a pharmaceutically acceptable carrier. Preferably, the effector is a quinazolinone derivative. More preferably, the quinazolinone derivative is a member of a group having formula (I), wherein R 1 is a member of the group consisting of hydrogen, halogen, nitro, benzo, lower alkyl, phenyl, and lower alkoxy; R 2 is a member of the group consisting of hydroxy, acetoxy, and lower alkoxy, and R 3 is a member of the group consisting of hydrogen and lower alkenoxy; and pharmaceutically acceptable salts thereof; and n is either 1 or 2. Most preferably, the effector is Halofuginone and pharmaceutically acceptable salts thereof.
• COMPOSITION AND METHOD FOR TREATING OR PREVENTING SKELETAL MUSCLE FIBROSIS
  申请人：Pines Mark

  公开号：US20100144766A1

  公开（公告）日：2010-06-10

  A compound in combination with a pharmaceutically acceptable carrier, the compound having a formula: wherein: R 1 is a member of the group consisting of hydrogen, halogen, nitro, benzo, lower alkyl, phenyl, and lower alkoxy; R 2 is a member of the group consisting of hydroxy, acetoxy, and lower alkoxy; and R 3 is a member of the group consisting of hydrogen and lower alkenoxy-carbonyl; and n is either 1 or 2; and pharmaceutically acceptable salts thereof; for use in treatment of or prevention of skeletal muscle fibrosis and/or for inducing skeletal muscle regeneration.
• PREVENTION OF RECURRENCE OF URETHRAL STRICTURE AFTER A CONVENTIONAL TREATMENT
  申请人：Jaidane Mehdi

  公开号：US20100305144A1

  公开（公告）日：2010-12-02

  Prevention of recurrence of urethral stricture after a conventional treatment. Composition applicable to the prevention of recurrence of urethral stricture after a conventional treatment, including a pharmaceutically effective amount of halofuginone. Urethral stricture, a common disease, appears secondary to urethritis, urethral infection, urethral inflammation, urethral instrumentation, urethral catheterization, urethral trauma, urethral surgery and all types of urethral lesions. Conventional treatments by internal urethrotomy, urethral dilation or surgical urethroplasty are available and can cure urethral stricture, but with a relatively high rate of recurrence of the stricture. Halofuginone can prevent the recurrence of urethral stricture after a conventional treatment via internal urethrotomy, urethral dilation or surgical urethroplasty.
• PREVENTION OF RECURRENCES OF URETHRAL STRICTURES FOLLOWING CONVENTIONAL THERAPY
  申请人：JAIDANE Mehdi

  公开号：US20140288102A1

  公开（公告）日：2014-09-25

  The instant invention relates to the prevention of recurrence of urethral stricture after a conventional treatment. Compositions applicable to the prevention of recurrence of urethral stricture after as conventional treatment, including a pharmaceutically effective amount of halofuginone, are disclosed. Urethral stricture, as common disease, appears secondary to urethritis, urethral infection, urethral inflammation, urethral instrumentation, urethral catheterization, urethral trauma, urethral surgery and all types of urethral lesions. Conventional treatments by internal urethrotomy, urethral dilatation or surgical urethroplasty are available and can cure urethral stricture, but with a relatively high rate of recurrence of the stricture. Halofuginone can prevent the recurrence of urethral stricture after conventional treatment via internal urethrotomy, urethral dilatation or surgical urethroplasty.
• US8410120B2
  申请人：——

  公开号：US8410120B2

  公开（公告）日：2013-04-02